Navigation Links
Genomatix technology facilitates de novo identification of new renal disease associated genes

Previously unknown molecules and regulatory pathways in human glomerular diseases have been identified by a joint effort of the Medizinische Poliklinik, Munich, the University of Bristol´s Children´s Renal Unit, the German Cancer Research Center, sanofi-aventis, and Genomatix Software GmbH.

In a joint publication in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) above groups show how new bioinformatics approaches allow rapid characterization of shared promoter structures which can be used to find novel interacting molecules. Here, these principles are applied to a set of genes linked to the unique functional unit of the glomerular slit diaphragm. An evolutionarily conserved promoter model was generated. Genome-wide scans using this promoter model effectively predicted a previously unrecognized slit diaphragm molecule which was then experimentally verified.

This publication shows a straightforward approach how comparative promoter analysis can identify regulatory pathways at work in tissue homeostasis and disease processes.


'"/>

Source:Genomatix Software GmbH


Page: 1

Related biology news :

1. Genomatix, AAAS ink agreement
2. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
3. MatBase -- A new transcription factor knowledge base released by Genomatix
4. Application of Genomatix in silico methods reveals novel cancer associated genes
5. Novel technology detects human DNA mutations
6. Novel antiviral technology inhibits RSV infection in mice
7. The BIOS Initiative - open source biotechnology is born
8. Revolutionary nanotechnology illuminates brain cells at work
9. Study: homemade gene expression technology unreliable
10. First technology to remove prions that cause vCJD from blood launched
11. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology: